Macguire Cheswick & Tuttle Investment Counsel LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, HoldingsChannel reports. The fund acquired 4,810 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

Other hedge funds have also recently bought and sold shares of the company. Morgan Stanley increased its holdings in Pfizer by 2.5% in the second quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock worth $1,972,442,000 after buying an additional 1,345,528 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Pfizer by 15.0% in the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after buying an additional 7,059,171 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Pfizer by 2.6% in the third quarter. Fisher Asset Management LLC now owns 40,477,731 shares of the biopharmaceutical company’s stock worth $1,783,854,000 after buying an additional 1,032,614 shares during the last quarter. LSV Asset Management increased its holdings in Pfizer by 2.7% in the second quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock worth $1,334,182,000 after buying an additional 973,497 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Pfizer by 1.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 35,137,579 shares of the biopharmaceutical company’s stock worth $1,274,792,000 after buying an additional 381,615 shares during the last quarter. 70.61% of the stock is owned by institutional investors.

In other news, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total value of $1,598,172.00. Following the completion of the sale, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at $3,443,154.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the completion of the sale, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at $3,573,558. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Shares of PFE stock opened at $42.23 on Monday. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $46.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $251.39 billion, a price-to-earnings ratio of 14.08, a P/E/G ratio of 2.42 and a beta of 0.77.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.63 by $0.01. Pfizer had a return on equity of 25.38% and a net margin of 20.79%. The company had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. During the same quarter last year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

Pfizer announced that its board has authorized a stock repurchase plan on Friday, December 14th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.41%. The ex-dividend date is Thursday, January 31st. This is an increase from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio (DPR) is 48.00%.

A number of equities analysts recently commented on the company. Credit Suisse Group restated a “neutral” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, January 28th. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a report on Wednesday, October 17th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. BMO Capital Markets downgraded Pfizer from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $47.00 to $46.00 in a report on Thursday, November 1st. They noted that the move was a valuation call. Finally, Wolfe Research assumed coverage on Pfizer in a report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $44.68.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2019/02/11/macguire-cheswick-tuttle-investment-counsel-llc-acquires-new-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Cost of Equity

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.